SG10202009424TA - Radio-pharmaceutical complexes - Google Patents
Radio-pharmaceutical complexesInfo
- Publication number
- SG10202009424TA SG10202009424TA SG10202009424TA SG10202009424TA SG10202009424TA SG 10202009424T A SG10202009424T A SG 10202009424TA SG 10202009424T A SG10202009424T A SG 10202009424TA SG 10202009424T A SG10202009424T A SG 10202009424TA SG 10202009424T A SG10202009424T A SG 10202009424TA
- Authority
- SG
- Singapore
- Prior art keywords
- radio
- pharmaceutical complexes
- complexes
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162123 | 2016-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202009424TA true SG10202009424TA (en) | 2020-11-27 |
Family
ID=55745553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009424TA SG10202009424TA (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
| SG11201806548UA SG11201806548UA (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806548UA SG11201806548UA (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11260136B2 (en) |
| EP (1) | EP3432936A1 (en) |
| JP (2) | JP2019513699A (en) |
| CN (1) | CN108778347A (en) |
| AR (1) | AR107957A1 (en) |
| AU (1) | AU2017239018A1 (en) |
| BR (1) | BR112018069485A2 (en) |
| CA (1) | CA3018607A1 (en) |
| CL (1) | CL2018002695A1 (en) |
| CO (1) | CO2018010024A2 (en) |
| IL (1) | IL261329B (en) |
| JO (1) | JOP20170072B1 (en) |
| MX (1) | MX2018011629A (en) |
| PE (1) | PE20190168A1 (en) |
| SG (2) | SG10202009424TA (en) |
| TW (1) | TWI757273B (en) |
| UA (1) | UA125749C2 (en) |
| UY (1) | UY37167A (en) |
| WO (1) | WO2017162555A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3432936A1 (en) * | 2016-03-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
| CA3110754A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| WO2020169537A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4880615A (en) | 1988-11-25 | 1989-11-14 | Merck & Co., Inc. | Stabilized radiopharmaceutical compositions |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| NO312708B1 (en) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioactive liposomes for therapy |
| NO313180B1 (en) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Visiting alpha particles emitting radiopharmaceuticals |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| RS53128B (en) * | 2005-02-23 | 2014-06-30 | Genentech Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| KR20080003388A (en) * | 2005-04-01 | 2008-01-07 | 메드벳 싸이언스 피티와이. 리미티드 | A method of diagnosis and treatment and agents useful for same |
| ES2613957T3 (en) * | 2006-08-04 | 2017-05-29 | Medimmune Limited | Antibodies against ERBB2 |
| WO2008063721A2 (en) | 2006-08-15 | 2008-05-29 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
| AU2010306774A1 (en) * | 2009-10-14 | 2012-05-03 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| MA41176A (en) * | 2014-12-17 | 2017-10-24 | Bayer As | RADIO-PHARMACEUTICAL COMPLEXES |
| EP3432936A1 (en) * | 2016-03-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
-
2017
- 2017-03-20 EP EP17710976.6A patent/EP3432936A1/en active Pending
- 2017-03-20 US US16/087,040 patent/US11260136B2/en active Active
- 2017-03-20 UA UAA201810278A patent/UA125749C2/en unknown
- 2017-03-20 BR BR112018069485A patent/BR112018069485A2/en unknown
- 2017-03-20 WO PCT/EP2017/056503 patent/WO2017162555A1/en active Application Filing
- 2017-03-20 MX MX2018011629A patent/MX2018011629A/en unknown
- 2017-03-20 CN CN201780017966.8A patent/CN108778347A/en active Pending
- 2017-03-20 SG SG10202009424TA patent/SG10202009424TA/en unknown
- 2017-03-20 PE PE2018001861A patent/PE20190168A1/en unknown
- 2017-03-20 JP JP2018547324A patent/JP2019513699A/en active Pending
- 2017-03-20 CA CA3018607A patent/CA3018607A1/en active Pending
- 2017-03-20 AU AU2017239018A patent/AU2017239018A1/en not_active Abandoned
- 2017-03-20 SG SG11201806548UA patent/SG11201806548UA/en unknown
- 2017-03-21 TW TW106109303A patent/TWI757273B/en active
- 2017-03-22 JO JOP/2017/0072A patent/JOP20170072B1/en active
- 2017-03-23 AR ARP170100720A patent/AR107957A1/en unknown
- 2017-03-23 UY UY0001037167A patent/UY37167A/en not_active Application Discontinuation
-
2018
- 2018-08-22 IL IL261329A patent/IL261329B/en active IP Right Grant
- 2018-09-24 CO CONC2018/0010024A patent/CO2018010024A2/en unknown
- 2018-09-24 CL CL2018002695A patent/CL2018002695A1/en unknown
-
2022
- 2022-01-21 US US17/581,808 patent/US20220143229A1/en active Pending
- 2022-08-30 JP JP2022136797A patent/JP2022173214A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11260136B2 (en) | 2022-03-01 |
| EP3432936A1 (en) | 2019-01-30 |
| CN108778347A (en) | 2018-11-09 |
| TW201736389A (en) | 2017-10-16 |
| JOP20170072B1 (en) | 2022-03-14 |
| JP2019513699A (en) | 2019-05-30 |
| IL261329B (en) | 2021-04-29 |
| JP2022173214A (en) | 2022-11-18 |
| AU2017239018A1 (en) | 2018-08-16 |
| MX2018011629A (en) | 2019-03-14 |
| WO2017162555A1 (en) | 2017-09-28 |
| BR112018069485A2 (en) | 2019-07-30 |
| CL2018002695A1 (en) | 2019-01-18 |
| US20220143229A1 (en) | 2022-05-12 |
| CO2018010024A2 (en) | 2018-10-22 |
| UY37167A (en) | 2017-10-31 |
| UA125749C2 (en) | 2022-06-01 |
| US20190091354A1 (en) | 2019-03-28 |
| TWI757273B (en) | 2022-03-11 |
| PE20190168A1 (en) | 2019-02-01 |
| CA3018607A1 (en) | 2017-09-28 |
| SG11201806548UA (en) | 2018-08-30 |
| AR107957A1 (en) | 2018-07-04 |
| IL261329A (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263538A (en) | Radio-pharmaceutical complexes | |
| IL252244B (en) | Radio-pharmaceutical complexes | |
| GB201504784D0 (en) | Complexes | |
| IL261329B (en) | Radio-pharmaceutical complexes | |
| GB201617103D0 (en) | Compound | |
| ZA201804206B (en) | Amylose-lipid complexes | |
| GB201504771D0 (en) | Complexes | |
| GB201509847D0 (en) | Anti-dandruff agents | |
| GB201509848D0 (en) | Anti-dandruff Agents | |
| HK1253336A1 (en) | Indolotryptoline anticancer agents | |
| GB2546773B (en) | Cancer | |
| GB201610497D0 (en) | Compound | |
| SG11201610339YA (en) | Metal complexes | |
| GB201509849D0 (en) | Anti-dandruff agents | |
| HK1252537A1 (en) | Acaricides | |
| GB201609707D0 (en) | Metal complexes | |
| EP3344661C0 (en) | Iron-polysaccharide complexes and methods for the preparation thereof | |
| GB201621692D0 (en) | Anti Cancer Agents | |
| GB201619526D0 (en) | Compound | |
| GB201619531D0 (en) | Compound | |
| GB201620135D0 (en) | Concept nine | |
| HUE052800T2 (en) | Contrast agents | |
| GB201613035D0 (en) | Compound | |
| GB201614244D0 (en) | Tjti&tjtd | |
| GB201614243D0 (en) | Tjti&tjtd |